Discussion  by unknown
anism of differentiation of stem cells should be investigated
more deeply in future studies.
We used neonatal cardiomyocytes because we wanted to
see contractions not seen in adult cardiomyocytes in vitro.
The combination of adult cardiomyocytes and GFP-BMCs
might be evaluated later.
The present study provides the first demonstration, to our
knowledge, of the cardiomyogenic differentiation of BMCs
without any chemicals in vitro. Using this coculture, we
might be able to identify specific substances regulating
cardiac development in the future.
We thank Ms K. Hattori for her help in breeding the GFP mice.
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Discussion
Dr Frank W. Sellke (Boston, Mass). How do you know that it
is due to direct cell-to-cell contact or interaction and that there is
not some substance secreted that causes this effect?
Dr Tomita. Of course, from only the observation under the
microscope, we do not know about that in detail. Some unknown
soluble factors might go through gap junctions, and we speculated
another mechanism of induction. We saw some TnI–positive cells
derived from GFP-BMCs attached to GFP-negative cells, which
were TnI negative. This observation suggested that some BMCs
differentiated to cardiomyocytes by means of mechanical stretch-
ing. Therefore, there are several inducers in this system.
Dr Henry M. Spotnitz (New York, NY). What do you think the
mediators are of this effect that are passing through the gap
junctions?
Dr Tomita. Thus far I have no concrete evidence.
Dr Spotnitz. You are sure that these cells are being trans-
formed and that they are not really myocytes?
Dr Tomita. Do you mean that the phenomenon is due to
fusion?
Dr Spotnitz. Yes.
Dr Tomita. There were landmark articles regarding fusion
between embryonic stem cells and BMCs published in the journal
Nature in April. They include a warning that reported differenti-
ation might be due to fusion.But in this study we just cultured
cardiomyocytes and BMCs and not embryonic stem cells. Of
course there are some possibilities, but embryonic stem cells are
very energetic and immature. They are easy to communicate, and
in the in vivo situation we put BMCs in the adult heart. They are
not embryonic stem cells. Therefore, it is a different story.
Dr Marcio Scorsin (Curitiba, Brazil). I have some doubts
concerning the fate of transplanted BMCs into a myocardial in-
farction scar. It is widely accepted that those cells might have a
milieu-dependent differentiation (becoming cardiomyocytes) in
normal myocardium. However, if you inject those cells into a
myocardial scar, according to some studies, they would produce
angiogenesis and differentiate into fibroblasts instead of cardio-
myocytes. My question is whether you think that it is important to
differentiate BMCs before transplantation.
Dr Tomita. For the in vivo study, it is not necessary to convert
all BMCs into cardiomyocytes. For example, if you put BMCs into
the scar, they might go in like myofibroblasts, but the myofibro-
blasts are also important to prevent extension of the scar. I saw
some TnI–positive cells from transplanted BMCs in the scar tissue
in the previous study. I agree to the hypothesis that fibroblasts are
strong inducers for BMCs to transform to fibroblasts.
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In terms of the strategy for the differentiation with BMCs, I do
not know which is stronger for the differentiation, either the in
vitro condition or the in vivo condition. However, when we think
about the cell process for the clinical reality, it might be difficult
to control preferable cell types in vitro under GMP regulation.
Therefore, it might be more practical to manipulate cells in the in
vivo environment.
Dr Marc J. H. Hendrikx (Hasselt, Belgium). If you did not
use a coculture but just differentiated your BMCs by using 5-aza-
cytidine, would you get the same expression of cardiac markers?
Do you have any ideas about that?
Dr Tomita. We reported the BMC differentiation using
5-azacytidine in the journal Circulation in 1999, but in this
study I just cultured in the cardiac environmental setting.
Therefore, I did not use 5-azacytidine in this study. In the next
step, we are considering using 5-azacytidine. It might increase
the number of induced cardio-specific cells in the coculture
system.
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